$162 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 51 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 82.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Sell | AMICUS THERAPEUTICS | $25,116,000 | +17.5% | 1,775,000 | -9.6% | 15.53% | -13.7% |
| AGTC | New | APPLIED GENETIC TECHNOL | $11,474,000 | – | 748,000 | +100.0% | 7.09% | – |
| VCYT | New | VERACYTE | $8,891,000 | – | 798,100 | +100.0% | 5.50% | – |
| IWM | Buy | ISHARES TRput | $8,739,000 | +251.4% | 70,000 | +250.0% | 5.40% | +157.9% |
| LBIO | Buy | LION BIOTECHNOLOGIES | $8,125,000 | +0.3% | 886,000 | +32.4% | 5.02% | -26.4% |
| ASND | Buy | ASCENDIS PHARMA A Sspons adr | $7,458,000 | +88.0% | 421,851 | +84.5% | 4.61% | +38.1% |
| BEAT | Buy | BIOTELEMETRY | $6,224,000 | +46.2% | 660,000 | +37.2% | 3.85% | +7.3% |
| SPNC | New | SPECTRANETICS | $5,753,000 | – | 250,000 | +100.0% | 3.56% | – |
| Buy | NEURODERM ORD SHS | $4,605,000 | +232.5% | 300,000 | +190.8% | 2.85% | +144.0% | |
| ALIM | Sell | ALIMERA SCIENCES | $4,492,000 | -15.0% | 974,318 | -7.6% | 2.78% | -37.6% |
| AGEN | New | AGENUS | $3,831,000 | – | 443,868 | +100.0% | 2.37% | – |
| SRNE | New | SORRENTO THERAPEUTICS | $3,743,000 | – | 212,402 | +100.0% | 2.31% | – |
| INNL | Buy | INNOCOLL AG SPONSORED ADRspons adr | $3,472,000 | +165.6% | 237,287 | +44.3% | 2.15% | +95.0% |
| AXGT | New | AXOVANT SCIENCES | $3,465,000 | – | 170,000 | +100.0% | 2.14% | – |
| BBW | Buy | BUILD A BEAR WORKSHOP | $3,198,000 | +8.5% | 200,000 | +33.3% | 1.98% | -20.4% |
| RRM | Buy | RR MEDIA SHS | $3,083,000 | -0.7% | 410,000 | +1.1% | 1.91% | -27.1% |
| AVID | Buy | AVID TECHNOLOGY | $3,068,000 | +104.3% | 230,000 | +128.1% | 1.90% | +50.0% |
| LMAT | Sell | LEMAITRE VASCULAR | $3,015,000 | -22.8% | 250,000 | -46.4% | 1.86% | -43.4% |
| CASM | Buy | CAS MED SYS PAR $0.004 | $3,015,000 | +4.5% | 2,355,355 | +9.0% | 1.86% | -23.3% |
| BIOD | New | BIODEL | $2,973,000 | – | 2,886,731 | +100.0% | 1.84% | – |
| IG | New | IGI LABS | $2,917,000 | – | 462,944 | +100.0% | 1.80% | – |
| CYNA | New | CYNAPSUS THERAPEUTICS INC | $2,763,000 | – | 169,616 | +100.0% | 1.71% | – |
| OXFD | Sell | OXFORD IMMUNOTEC GLOBAL PLC | $2,738,000 | -12.5% | 197,680 | -11.0% | 1.69% | -35.7% |
| IRIX | Buy | IRIDEX | $2,578,000 | +2.5% | 312,450 | +32.7% | 1.59% | -24.7% |
| ONTY | New | ONCOTHYREON | $2,506,000 | – | 670,000 | +100.0% | 1.55% | – |
| COLL | New | COLLEGIUM PHARMACEUTICAL | $2,319,000 | – | 130,000 | +100.0% | 1.43% | – |
| ZFGN | Sell | ZAFGEN | $1,832,000 | -53.7% | 52,900 | -47.1% | 1.13% | -66.0% |
| CDTX | New | CIDARA THERAPEUTICS | $1,823,000 | – | 130,000 | +100.0% | 1.13% | – |
| AUPH | Buy | AURINIA PHARMACEUTICALS | $1,585,000 | -15.5% | 524,751 | +22.0% | 0.98% | -37.9% |
| FLKS | Sell | FLEX PHARMA | $1,526,000 | -13.5% | 88,716 | -1.4% | 0.94% | -36.5% |
| CBMX | COMBIMATRIX CORPORATION | $1,417,000 | -15.3% | 880,244 | 0.0% | 0.88% | -37.8% | |
| EGOV | Buy | NIC | $1,280,000 | +26.7% | 70,000 | +22.5% | 0.79% | -7.1% |
| OTIC | Buy | OTONOMY | $1,228,000 | +73.7% | 53,400 | +167.0% | 0.76% | +27.6% |
| CUTR | New | CUTERA | $1,161,000 | – | 75,000 | +100.0% | 0.72% | – |
| HUM | New | HUMANA | $1,148,000 | – | 6,000 | +100.0% | 0.71% | – |
| AGRX | Buy | AGILE THERAPEUTICS | $1,104,000 | +47.2% | 128,566 | +58.8% | 0.68% | +8.1% |
| CRDC | Buy | CARDICA | $923,000 | -19.5% | 1,849,436 | +1.6% | 0.57% | -40.8% |
| HSGX | HISTOGENICS | $796,000 | -35.3% | 123,249 | 0.0% | 0.49% | -52.6% | |
| AWAY | New | HOMEAWAY | $778,000 | – | 25,000 | +100.0% | 0.48% | – |
| VSAR | New | VERSARTIS | $761,000 | – | 50,000 | +100.0% | 0.47% | – |
| SGNT | New | SAGENT PHARMACEUTICALS | $681,000 | – | 28,000 | +100.0% | 0.42% | – |
| CEMI | Sell | CHEMBIO DIAGNOSTICS | $638,000 | +8.1% | 130,000 | -11.0% | 0.39% | -20.7% |
| ZSAN | Buy | ZOSANO PHARMA | $632,000 | +184.7% | 87,189 | +297.1% | 0.39% | +109.1% |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCspons adr | $550,000 | – | 30,000 | +100.0% | 0.34% | – |
| CEMP | Sell | CEMPRA | $515,000 | -91.2% | 15,000 | -91.2% | 0.32% | -93.5% |
| New | ALCOBRA SHS | $458,000 | – | 70,039 | +100.0% | 0.28% | – | |
| KIN | Sell | KINDRED BIOSCIENCES | $341,000 | -36.4% | 50,000 | -33.3% | 0.21% | -53.2% |
| FOMX | New | FOAMIX PHARMACEUTICALS SHS | $308,000 | – | 30,000 | +100.0% | 0.19% | – |
| SMLR | Sell | SEMLER SCIENTIFIC | $267,000 | -33.7% | 80,935 | -29.7% | 0.16% | -51.3% |
| MOLGY | Sell | MOL GLOBAL SPONSORED ADRspons adr | $226,000 | -59.9% | 147,912 | -39.9% | 0.14% | -70.5% |
| SSH | New | SUNSHINE HEART INCput | $207,000 | – | 60,000 | +100.0% | 0.13% | – |
| TXMD | Exit | THERAPEUTICSMD | $0 | – | -18,915 | -100.0% | -0.10% | – |
| ANGO | Exit | ANGIODYNAMICS | $0 | – | -10,000 | -100.0% | -0.15% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS | $0 | – | -36,107 | -100.0% | -0.27% | – |
| SAGE | Exit | SAGE THERAPEUTICS | $0 | – | -8,000 | -100.0% | -0.34% | – |
| CERS | Exit | CERUS | $0 | – | -100,000 | -100.0% | -0.35% | – |
| GNVC | Exit | GENVEC | $0 | – | -154,508 | -100.0% | -0.38% | – |
| DSCO | Exit | DISCOVERY LABORATORIES | $0 | – | -393,148 | -100.0% | -0.39% | – |
| DYAX | Exit | DYAX CORPcall | $0 | – | -50,000 | -100.0% | -0.71% | – |
| EXEL | Exit | EXELIXIS INCcall | $0 | – | -329,000 | -100.0% | -0.71% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS | $0 | – | -593,872 | -100.0% | -0.72% | – |
| SRNE | Exit | SORRENTO THERAPEUTICScall | $0 | – | -80,000 | -100.0% | -0.78% | – |
| NXTM | Exit | NXSTAGE MEDICAL | $0 | – | -53,665 | -100.0% | -0.78% | – |
| RXDX | Exit | IGNYTA | $0 | – | -100,000 | -100.0% | -0.84% | – |
| BLCM | Exit | BELLICUM PHARMACEUTICALS | $0 | – | -43,986 | -100.0% | -0.86% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -10,000 | -100.0% | -1.74% | – |
| PODD | Exit | INSULET | $0 | – | -62,265 | -100.0% | -1.75% | – |
| OFIX | Exit | ORTHOFIX INTL N V | $0 | – | -60,000 | -100.0% | -1.81% | – |
| CRME | Exit | CARDIOME PHARMA | $0 | – | -237,600 | -100.0% | -1.85% | – |
| INSM | Exit | INSMED | $0 | – | -150,000 | -100.0% | -2.63% | – |
| PTX | Exit | PERNIX THERAPEUTICS HLDGS | $0 | – | -350,000 | -100.0% | -3.15% | – |
| Exit | EXELIXIS INCnote 4.25% 8/1 | $0 | – | -5,474,000 | -100.0% | -3.51% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.